Amylyx Pharmaceuticals, Inc. (AMLX)
NASDAQ: AMLX · Real-Time Price · USD
14.05
+0.26 (1.89%)
At close: Mar 19, 2026, 4:00 PM EDT
14.05
0.00 (0.00%)
After-hours: Mar 19, 2026, 4:02 PM EDT
Amylyx Pharmaceuticals Employees
Amylyx Pharmaceuticals had 136 employees as of December 31, 2025. The number of employees increased by 13 or 10.57% compared to the previous year.
Employees
136
Change (1Y)
13
Growth (1Y)
10.57%
Revenue / Employee
n/a
Profits / Employee
-$1,064,228
Market Cap
1.56B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 136 | 13 | 10.57% |
| Dec 31, 2024 | 123 | -261 | -67.97% |
| Dec 31, 2023 | 384 | 122 | 46.56% |
| Sep 30, 2023 | 374 | 137 | 57.81% |
| Jun 30, 2023 | 338 | 112 | 49.56% |
| Mar 31, 2023 | 296 | 91 | 44.39% |
| Dec 31, 2022 | 262 | 57 | 27.80% |
| Sep 30, 2022 | 237 | 127 | 115.45% |
| Jun 30, 2022 | 226 | 116 | 105.45% |
| Dec 31, 2021 | 205 | 171 | 502.94% |
| Sep 30, 2021 | 110 | 76 | 223.53% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Bausch Health Companies | 20,300 |
| Perrigo Company | 8,100 |
| Phibro Animal Health | 2,475 |
| HUTCHMED (China) | 1,796 |
| Alvotech | 1,012 |
| ANI Pharmaceuticals | 970 |
| Pacira BioSciences | 829 |
| Cronos Group | 610 |
AMLX News
- 14 days ago - Amylyx: LUCIDITY Trial Sets Stage For Q3 Inflection Point - Seeking Alpha
- 15 days ago - Amylyx Pharmaceuticals, Inc. (AMLX) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 16 days ago - Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results - Business Wire
- 21 days ago - Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences - Business Wire
- 23 days ago - Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026 - Business Wire
- 6 weeks ago - HALPER SADEH LLC ENCOURAGES AMYLYX PHARMACEUTICALS, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS - PRNewsWire
- 2 months ago - Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra A/S - Business Wire
- 3 months ago - Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA Trial - Business Wire